Palisade Bio (PALI) 10-Q 7 Nov 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'Neuralstem, Inc.	'
Entity Central Index Key	'0001357459	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Trading Symbol	'CUR	'
Entity Common Stock, Shares Outstanding	'	87,359,665

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
CURRENT ASSETS	'	'
Cash and cash equivalents	$11,945,253	$16,846,052
Short-term investments	15,007,478	0
Billed and unbilled receivables	32,761	10,000
Deferred financing fees, current portion	339,752	507,334
Prepaid expenses	409,140	255,733
Total current assets	27,734,384	17,619,119
Property and equipment, net	301,282	230,971
Patents, net	1,245,502	1,137,701
Deferred financing fees, net of current portion	104,407	360,848
Other assets	57,720	64,897
Total assets	29,443,295	19,413,536
CURRENT LIABILITIES	'	'
Accounts payable and accrued expenses	2,444,039	1,662,058
Current portion of long term debt, net of discount	3,058,495	2,763,121
Derivative instruments	0	1,417,527
Other current liabilities	202,383	93,426
Total current liabilities	5,704,917	5,936,132
Long term debt, net of discount and current portion	2,611,421	4,934,210
Other long term liabilities	222,970	124,995
Total liabilities	8,539,308	10,995,337
Commitments and contingencies (Note 6)	'	'
STOCKHOLDERS' EQUITY	'	'
Preferred stock, 7,000,000 shares authorized, zero shares issued and outstanding	0	0
Common stock, $0.01 par value; 300 million shares authorized, 87,155,672 and 77,886,031 shares outstanding in 2014 and 2013, respectively	871,557	778,860
Additional paid-in capital	165,577,933	136,058,135
Accumulated other comprehensive income	6,110	7,241
Accumulated deficit	-145,551,613	-128,426,037
Total stockholders' equity	20,903,987	8,418,199
Total liabilities and stockholders' equity	$29,443,295	$19,413,536

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets [Parenthetical] (USD $)	Sep. 30, 2014	Dec. 31, 2013
Preferred stock, shares authorized	7,000,000	7,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares outstanding	87,155,672	77,886,031

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues	$5,000	$2,500	$14,167	$107,500
Operating expenses:	'	'	'	'
Research and development expenses	2,058,865	1,847,403	5,577,644	5,502,137
General and administrative expenses	1,969,879	1,707,690	6,971,186	4,184,740
Depreciation and amortization	83,001	81,393	260,221	181,991
Total operating expenses	4,111,745	3,636,486	12,809,051	9,868,868
Operating loss	-4,106,745	-3,633,986	-12,794,884	-9,761,368
Other income (expense):	'	'	'	'
Interest income	13,127	18,776	55,267	45,336
Interest expense	-361,619	-448,943	-1,191,976	-936,471
Warrant modification expense	0	-1,945,214	-3,109,850	-5,017,156
Loss from change in fair value of derivative instruments	0	-677,883	-334,133	-859,682
Other income	0	293	250,000	667
Total other income (expense)	-348,492	-3,052,971	-4,330,692	-6,767,306
Net loss	-4,455,237	-6,686,957	-17,125,576	-16,528,674
Net loss per common share - basic and diluted (in dollars per share)	($0.05)	($0.09)	($0.20)	($0.23)
Weighted average common shares outstanding - basic and diluted (in shares)	87,366,234	72,986,698	86,777,197	70,533,035
Comprehensive loss:	'	'	'	'
Net loss	-4,455,237	-6,686,957	-17,125,576	-16,528,674
Foreign currency translation adjustment	3	6,101	-1,131	6,101
Comprehensive loss	($4,455,234)	($6,680,856)	($17,126,707)	($16,522,573)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($17,125,576)	($16,528,674)
Adjustments to reconcile net loss to cash used in operating activities:	'	'
Depreciation and amortization	260,221	181,991
Share based compensation expense	3,638,972	2,080,740
Amortization of deferred financing fees and debt discount	622,244	462,794
Warrant modification expense	3,109,850	5,017,156
Loss from change in fair value of derivative instruments	334,133	859,682
Changes in operating assets and liabilities:	'	'
Billed and unbilled receivables	-22,761	-4,167
Prepaid expenses	56,221	38,849
Other assets	7,131	-5,172
Accounts payable and accrued expenses	899,299	-191,686
Other current liabilities	3,191	-18,541
Other long term liabilities	-9,261	-8,651
Net cash used in operating activities	-8,226,336	-8,115,679
Cash flows from investing activities:	'	'
Purchases of short-term investments	-25,007,478	0
Maturity of short-term investments	10,000,000	'
Patent costs	-308,136	-325,783
Purchase of property and equipment	-172,171	-118,938
Net cash used in investing activities	-15,487,785	-444,721
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock from warrants exercised	1,661,865	5,836,346
Proceeds from issuance of common stock from options exercised	133,000	0
Proceeds from sale of common stock and warrants, net of issuance costs	19,467,859	4,241,640
Proceeds from long term debt, net of issuance costs	0	7,551,329
Payment of taxes on stock option exercise	-426,212	0
Payments of long term debt	-1,917,353	0
Payments of short term notes payable	-104,957	-81,362
Prepayment of equity financing fees	0	-35,000
Net cash provided by financing activities	18,814,202	17,512,953
Effects of exchange rates on cash	-880	5,402
Net increase (decrease) in cash and cash equivalents	-4,900,799	8,957,955
Cash and cash equivalents, beginning of period	16,846,052	7,443,773
Cash and cash equivalents, end of period	11,945,253	16,401,728
Supplemental disclosure of cash flow information:	'	'
Cash paid for interest	573,869	399,960
Supplemental schedule of non cash investing and financing activities:	'	'
Issuance of warrants for vendor services	0	658,326
Issuance of common stock for cashless exercise of warrants	838,213	587,500
Issuance of common stock for cashless exercise of options	369,867	0
Issuance of common stock for fees related to debt issuance	0	396,234
Issuance of warrants for fees related to debt issuance	0	452,187
Financing of insurance premiums through note payable	$210,722	$183,472

Basis_of_Presentation_and_Liqu

Basis of Presentation and Liquidity	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	'
	Note 1.   Basis of Presentation and Liquidity
	In management’s opinion, the accompanying condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed consolidated balance sheet at December 31, 2013, has been derived from audited financial statements as of that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (“SEC”). We believe that the disclosures provided herein are adequate to make the information presented not misleading when these condensed consolidated financial statements are read in conjunction with the Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2013, filed with the SEC on March 10, 2014, and as may be amended.
	Neuralstem, Inc. is referred to as “Neuralstem,” the “Company,” “us,” or “we” throughout this report. Beginning in the quarter ended September 30, 2013, our investment in, and the operations of, our wholly-owned and controlled subsidiary located in China are consolidated in our condensed consolidated financial statements; previously, all investments in China were expensed as incurred. The impact of this change was not material in any period presented.
	Our operations currently do not generate significant cash. Our management does not know when or if this will change. We have spent and will continue to spend substantial funds in the research, development, clinical and pre-clinical testing of our stem cell and small molecule product candidates with the goal of ultimately obtaining approval from the United States Food and Drug Administration (the “FDA”), to market and sell our proposed products. While we believe our cash position is inadequate to fund all of the costs associated with the full range of testing and clinical trials required by the FDA for our current product candidates, we anticipate that our available cash and expected income will be sufficient to finance our current activities through at least September 30, 2015.
	No assurance can be given that (i) FDA approval will ever be granted for us to market and sell our product candidates, or (ii) if FDA approval is granted, that we will ever be able to sell our proposed products or be profitable.

Significant_Accounting_Policie

Significant Accounting Policies and Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 2.  Significant Accounting Policies and Recent Accounting Pronouncements
	Use of Estimates
	The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The condensed consolidated financial statements include significant estimates for the expected economic life and value of our licensed technology, our net operating loss carry forward and related valuation allowance for tax purposes and our stock-based compensation related to employees and directors, consultants and advisors, including investment banks, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.
	Fair Value Measurements
	The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, other short-term investments, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The fair value of our long-term indebtedness is estimated based on the quoted prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. The fair values of our derivative instruments are estimated using Level 3 unobservable inputs. See Note 3 for further details.
	Foreign Currency Translation
	The functional currency of our wholly owned foreign subsidiary is its local currency.  Assets and liabilities of our foreign subsidiary are translated into United States dollars based on exchange rates at the end of the reporting period; income and expense items are translated at the weighted average exchange rates prevailing during the reporting period.  Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of are accumulated in other comprehensive income or loss, a component of stockholders' equity.   Transaction gains or losses are included in the determination of net loss.
	Cash, Cash Equivalents, Short-Term Investments and Credit Risk
	Cash equivalents consist of investments in low risk, highly liquid money market funds and certificates of deposit with original maturities of 90 days or less. Cash deposited with banks and other financial institutions may exceed the amount of insurance provided on such deposits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.
	Short-term investments consist entirely of fixed income certificates of deposit (“CDs”) with original maturities of greater than 90 days and not more than one year. The Company did not have any short-term investments at December 31, 2013.
	Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents and short-term investments. Our investment policy, approved by our Board of Directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. In addition, our CDs are invested through the Certificate of Deposit Account Registry Service (“CDARS”) program which reduces or eliminates our risk related to concentrations of investments above FDIC insurance levels. We limit our credit and liquidity risks through our investment policy and through regular reviews of our portfolio against our policy. To date, we have not experienced any loss or lack of access to cash in our operating accounts or to our cash equivalents and short-term investments.
	Revenue Recognition
	Historically, our revenue has been derived primarily from (i) selling treated samples for gene expression data from stem cell experiments, (ii) providing services under various contracts and grants and (iii) licensing the use of our intellectual property to third parties. Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery of goods and services has occurred, the price is fixed and determinable, and collection is reasonably assured.
	Research and Development
	Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of costs associated exclusively with the pre-clinical development and clinical trials of our product candidates.
	Income (Loss) per Common Share
	Basic income (loss) per common share is computed by dividing total net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
	For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of stock options, restricted stock units and common stock purchase warrants. The dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. Our unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator.
	For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share for the three- and nine-month periods ended September 30, 2014 and 2013. A total of approximately 40.1 million and 36.1 million potential dilutive shares have been excluded in the calculation of diluted net income per share for the three- and nine-month periods ended September 30, 2014 and 2013, respectively, as their inclusion would be anti-dilutive.
	Share-Based Compensation
	We account for share-based compensation at fair value. Share-based compensation cost for stock options and warrants is determined at the grant date using an option pricing model that uses Level 3 unobservable inputs; share-based compensation cost for restricted stock and restricted stock units is determined at the grant date based on the closing price of our common stock on that date. The value of the award that is ultimately expected to vest is recognized as an expense on a straight-line basis over the requisite service period.
	Intangible and Long-Lived Assets
	We assess impairment of our long-lived assets using a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. During the three- and nine-month periods ended September 30, 2014 and 2013, no impairment losses were recognized.
	Income Taxes
	We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. Our income tax returns for the past three years are subject to examination by tax authorities and may change upon examination.
	Significant New Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (FASB) issued ASU 2014-09 – Revenue from Contracts with Customers. This guidance is effective for fiscal years beginning after December 15, 2016 and early adoption is not permitted. We have not yet determined the effects of this new guidance on our financial statements.
	In August 2014, the FASB issued ASU 2014 – Presentation of Financial Statements – Going Concern. This guidance requires management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. This guidance is effective for fiscal years beginning after December 15, 2016 and early adoption is permitted. We do not expect the adoption of this guidance to have a material impact on our financial statements.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	Note 3.  Fair Value Measurements
	Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These levels are:
		·	Level 1 – inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.
		·	Level 2 – inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques (e.g. the Black-Scholes model) for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, foreign exchange rates, and forward and spot prices for currencies and commodities.
		·	Level 3 – inputs are generally unobservable and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models.
	Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
	We have segregated our financial assets and liabilities that are measured at fair value into the most appropriate levels within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.
	The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of our funds. The fair value of other short-term financial instruments (primarily accounts receivable, short-term investments, inventory, prepaid expenses and other current assets, and accounts payable and accrued expenses) approximate their carrying values because of their short-term nature. The fair value of our long-term indebtedness approximates its carrying value.
	At December 31, 2013, we had common stock purchase warrants issued in conjunction with our March 2013 debt offering (see Note 4) that were accounted for as derivative instruments whose fair market value was determined using Level 3 inputs. These warrants were exercised in their entirety in the first quarter of 2014. In addition, in 2013 we issued certain stock options that were subject to shareholder approval at issuance and which approval was received later in 2013. These options were recorded as an accrued liability carried at fair market value using Level 3 inputs.
	The following table identifies the carrying amounts of such assets and liabilities at December 31, 2013:
			Level 1		Level 2		Level 3		Total
	Liabilities
	Derivative instruments - stock purchase warrants		$	-	$	-	$	1,417,527	$	1,417,527
			$	-	$	-	$	1,417,527	$	1,417,527
	We had no financial assets or liabilities measured at fair value on a recurring basis at September 30, 2014.
	The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 inputs for the nine months ended September 30, 2013 and 2014:
			Derivative		Contingent Stock
			Instruments - Stock		Options
			Purchase Warrants
	Balance at December 31, 2012		$	-	$	-
	Issuance			452,198		35,000
	Change in fair value			859,682		74,602
	Balance at September 30, 2013		$	1,311,880	$	109,602
			Derivative
			Instruments - Stock
			Purchase Warrants
	Balance at December 31, 2013		$	1,417,527
	Change in fair value			334,133
	Exercise of underlying warrants			-1,751,660
	Balance at September 30, 2014		$	-
	The (gains) losses resulting from the changes in the fair value of the derivative instruments are classified as the “change in the fair value of derivative instruments” in the accompanying condensed consolidated statements of operations. The change in fair value of the contingent stock options is classified as share-based compensation. The fair values of both the common stock purchase warrants and the contingent stock options are determined based on the Black-Scholes option pricing model for “plain vanilla” stock options and other option pricing models as appropriate, and includes the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may change the embedded conversion options’ fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in these unobservable inputs generally result in decreases in fair value.
	Non-Financial Assets and Liabilities Measure at Fair Value on a Recurring Basis
	We have no non-financial assets and liabilities that are measured at fair value on a recurring basis.
	Non-Financial Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis
	We measure our long-lived assets, including property and equipment and patent costs, at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be other-than-temporarily impaired. No such fair value impairment was recognized in the nine months ended September 30, 2014 or 2013.

Debt

Debt	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 4.   Debt
	In March 2013, we entered into a loan and security agreement for an initial $8 million term loan with an additional $2 million of borrowing capacity if certain conditions involving new partnerships are met. The loan is collateralized by substantially all of our assets, including our intellectual property.
	The loan provides for interest at a variable rate based on prime with a floor of 11% and matures in June 2016. The variable rate was 11% for the nine months ended September 30, 2014 and 2013. The loan calls for interest only payments through December 2013 at which time monthly principal and interest payments of approximately $300,000 began through maturity. The loan resulted in net proceeds of approximately $7,551,000 after origination and other cash fees and expenses related to the closing of the loan. At September 30, 2014, remaining principal payments due under this loan are approximately $763,000, $3,273,000 and $1,797,000 in 2014, 2015 and 2016, respectively.
	In September 2014, the lender elected to convert a principal payment of approximately $249,000 into 200,371 shares of our common stock in accordance with the terms of the loan and security agreement.
	In conjunction with the loan agreement, we issued the lender a five-year common stock purchase warrant to purchase 648,809 shares of common stock at an exercise price of $1.0789 per share. This warrant contained non-standard anti-dilution protection and, consequently, was being accounted for as a derivative instrument, recorded at fair market value each period (see Note 3). The allocation of proceeds to this warrant resulted in a debt discount which is being amortized as interest expense over the term of the debt using the effective interest method. The warrant was exercised in the first quarter of 2014.
	We also incurred expenses with various third parties in connection with the debt issuance, consisting of approximately $449,000 in cash, 350,650 shares of common stock valued at approximately $396,000, and a five-year common stock purchase warrant to purchase 648,798 shares at an exercise price of $1.07892 per share. The warrant is classified as equity. Fees related to the debt offering are recorded as deferred financing fees and are being amortized as interest expense over the term of the debt using the effective interest method.
	In October 2014, the Company refinanced and modified its long-term debt (see Note 7).

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 5.   Stockholders’ Equity
	We have granted share-based compensation awards to employees, board members and service providers. Awards may consist of common stock, restricted common stock, restricted common stock units, warrants, or stock options. Our stock options and warrants have lives of up to ten years from the grant date. The stock options and warrants vest either upon the grant date or over varying periods of time. The stock options we grant provide for option exercise prices equal to or greater than the fair market value of the common stock at the date of the grant. Restricted stock units grant the holder the right to receive fully paid common shares with various restrictions on the holder’s ability to transfer the shares. Vesting of the restricted stock units is similar to that of stock options. As of September 30, 2014, we have approximately 44.4 million shares of common stock reserved for issuance upon the exercise of such awards.
	Share-based compensation expense included in the statements of operations for the three and nine months ended September 30, 2014 and 2013 was as follows:
		Three Months Ended September 30,
		2014			2013
	Research and development expenses	$	245,000		$	241,934
	General and administrative expenses		411,947			765,519
	Total	$	656,947		$	1,007,453
		Nine Months Ended September 30,
		2014			2013
	Research and development expenses	$	723,558		$	690,199
	General and administrative expenses		2,915,414			1,390,541
	Total	$	3,638,972		$	2,080,740
	Included in general and administrative expenses for the nine months ended September 30, 2014 is approximately $2 million related to the extension of the term of a common stock purchase warrant based on the holder achieving certain performance based milestones.
	Stock Options A summary of stock option activity during the nine months ended September 30, 2014 is as follows:
		Number of Options			Weighted-		Weighted-		Aggregate
					Average		Average		Intrinsic Value
					Exercise		Remaining
					Price		Contractual
							Life (in years)
	Outstanding at January 1, 2014		18,577,207		$	1.79		5.8	$	24,000,710
	Granted		863,393		$	3.26
	Exercised		-322,231		$	0.89			$	1,310,344
	Forfeited		-282,789		$	1.2
	Outstanding at September 30, 2014		18,835,580		$	1.89		5.3	$	27,950,386
	Exercisable at September 30, 2014		14,014,963		$	2.07		4.4	$	18,523,332
	Vested and expected to vest		18,835,580		$	1.89		5.3	$	27,950,386
	Range of Exercise Prices	Number of Options			Weighted-		Weighted-		Aggregate
		Outstanding			Average		Average		Intrinsic Value
					Exercise		Remaining
					Price		Contractual
							Life (in years)
	$0.50 - $1.00		7,000,000		$	0.8		5.8	$	17,360,000
	$1.01 - $2.00		4,171,817		$	1.19		6.9		8,714,368
	$2.01 - $3.00		2,067,037		$	2.48		4.7		1,646,933
	$3.01 - $5.00		5,596,726		$	3.54		3.8		229,085
			18,835,580		$	1.89		5.3	$	27,950,386
	The Company uses the Black-Scholes option pricing model for “plain vanilla” options and other pricing models as appropriate to calculate the fair value of options. Significant assumptions used in these models include:
		Nine Months Ended September 30,
		2014		2013
	Annual dividend	-		-
	Expected life (in years)	4.0 - 8.5		3.0 - 6.0
	Risk free interest rate	1.12% - 2.50%		0.51% - 1.01%
	Expected volatility	68.8% - 100.0%		65.1% - 75.2%
	The options granted in the nine months ended September 30, 2014 and 2013 had weighted average grant date fair values of $1.93 and $0.69, respectively.
	Unrecognized compensation cost for unvested stock option awards outstanding at September 30, 2014 was approximately $4,708,000 to be recognized over approximately 2.2 years.
	RSUs We have granted restricted stock units (RSUs) that entitle the holders to receive shares of our common stock upon vesting and subject to certain restrictions regarding the exercise of the RSUs and the holders’ ability to transfer the shares received upon exercise. The fair value of RSUs granted is based upon the market price of the underlying common stock as if they were vested and issued on the date of grant.
	A summary of our restricted stock unit activity for the nine months ended September 30, 2014 is as follows:
		Number of			Weighted-
		RSU's			Average
					Grant Date
					Fair Value
	Outstanding at January 1, 2014		401,625		$	2.03
	Granted		50,000		$	3.31
	Vested and converted to common shares		-568		$	1.19
	Forfeited		-3,782		$	1.19
	Outstanding at September 30, 2014		447,275		$	2.18
	Exercisable at September 30, 2014		427,416		$	2.15
	Unrecognized compensation cost for unvested RSUs outstanding at September 30, 2014 was approximately $45,000 to be recognized over approximately 0.5 years.
	Stock Purchase Warrants We have issued common stock purchase warrants to certain stockholders and service providers. In addition, warrants were issued in conjunction with the March 2013 debt transaction. A summary of warrant activity for the nine months ended September 30, 2014 is as follows:
		Number of			Weighted-		Weighted-		Aggregate
		Warrants			Average		Average		Intrinsic
					Exercised		Remaining		Value
		Price			Contractual Life
					(in years)
Outstanding at January 1, 2014		19,586,819		$	1.96		3.4	$	21,146,495
Granted		3,586,435		$	3.66		4.3
Exercised		-1,624,449		$	1.36
Forfeited		-259,788		$	1.23
Outstanding at September 30, 2014		21,289,017		$	2.3		4	$	23,900,186
Exercisable at September 30, 2014		21,176,517		$	2.28		4	$	23,900,186
The stock purchase warrants granted in the nine months ended September 30, 2014 and 2013 had a weighted average grant date fair value of $2.09 and $0.82, respectively.
In the quarter ended June 2014 we modified certain warrants held by our Chief Science Officer. Such modification extended the term of the warrants by an additional five years and resulted in an expense of approximately $3.1 million included in other expense in our statements of operations for the nine-month period ended September 30, 2014.
Common Stock
In June 2014, the Company’s shareholders approved a 150,000,000 increase in the authorized shares of common stock bringing the total authorized shares of common stock to 300,000,000.
In January and February 2013, we issued 258,000 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.25 per share and we received approximately $323,000 in net proceeds from the exercises. In conjunction with the exercises, we modified the warrants to reduce the exercise price to $1.25 and issued 258,000 replacement warrants. The replacement warrants have an exercise price of $1.25 and expire in March 2020. We recognized an expense for the value of the replacement warrants and the reduction of the exercise price on the original warrants. Such expense is classified as warrant modification expense. The warrants are classified within equity.
In March 2013, we issued 350,650 shares of common stock and 1,297,607 common stock purchase warrants to various parties in conjunction with our debt transaction (see Note 4).
In May 2013, we issued 440,000 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.07 per share and we received approximately $433,000 in net proceeds from the exercises. In conjunction with the exercise, we modified the warrants to reduce the exercise price to $1.07 and issued 440,000 replacement warrants. The replacement warrants have an exercise price of $1.25 and expire in May 2016. We recognized expense for the value of the replacement warrants and the reduction of the exercise price on the original warrants; such expense is classified as warrant modification expense. The warrants are classified within equity.
In May 2013, we issued 689,675 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.25 per share and we received approximately $844,000 in net proceeds from the exercises. In conjunction with the exercises, we modified the warrants to reduce the exercise price to $1.25 and issued 689,675 replacement warrants. The replacement warrants have an exercise price of $1.25 and expire in March 2020. We recognized an expense for the value of the replacement warrants and the reduction of the exercise price on the original warrants; such expense is classified as warrant modification expense. The warrants are classified within equity.
In May and June 2013, we issued 378,809 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.25 per share and we received approximately $474,000 in net proceeds from the exercises. In conjunction with the exercise, we issued 378,809 replacement warrants. The replacement warrants have an exercise price of $1.25 and expire in March 2020. We recognized an expense for the value of the replacement warrants; such expense is classified as warrant modification expense. The warrants are classified within equity.
In May and June 2013, we issued 300,000 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.02 and we received approximately $306,000 in net proceeds from the exercises.
In July 2013, we issued 942,520 shares of our common stock upon the exercise of outstanding warrants. The shares were issued at $1.25 per share and we received approximately $1,178,000 in net proceeds from the exercises. In conjunction with the exercises, we modified 782,005 of the warrants to reduce the exercise price to $1.25 and issued 942,520 replacement warrants. The replacement warrants have an exercise price of $1.25 and expire in March 2020. We recognized an expense for the value of the replacement warrants and the reduction of the exercise price on the original warrants; such expense is classified as warrant modification expense. The warrants are classified within equity.
In July 2013, we issued 100,000 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.02 and we received approximately $102,000 in net proceeds from the exercise.
In September 2013, we issued 1,448,798 shares of common stock upon the exercise of outstanding warrants. The shares were issued at $1.25 per share (800,000 shares) and $1.08 per share (648,798 shares) and we received approximately $1,700,000 in net proceeds from the exercises. In conjunction with the exercise, we issued an additional 72,440 shares of our common stock as a commission for exercise. We recognized an expense for the value of the additional common stock; such expense is classified as warrant modification expense.
In September and December 2013, we issued 344,000 shares of common stock upon the exercise of outstanding warrants. Of these shares, 340,000 shares of stock were issued at $2.13 while 4,000 shares of stock were issued at $1.56. We received approximately $730,000 net proceeds from the exercises.
In September 2013, we issued 401,133 shares of our common stock as a result of the cashless exercise of 650,000 outstanding common stock purchase warrants with an average strike price of $0.90. The exercises resulted in 248,867 warrants being forfeited and we received no proceeds.
In September 2013, we completed a registered direct offering of 2,847,500 shares of common stock at a price of $1.60 per share. We received aggregate gross proceeds of $4,556,000 and net proceeds of approximately $4,242,000 from the offering. In connection with the offering, we issued common stock purchase warrants to purchase 1,423,750 shares of our common stock; the warrants have an exercise price of $2.00 and a term of five years. Additionally, we issued a common stock purchase warrant to the placement agent to purchase up to 170,850 shares; the warrant has an exercise price of $2.00 per share and term of 19 months. The warrants are classified within equity.
In November and December 2013, we issued 1,140,994 shares of common stock as a result of sales under our At the Market Offering Agreement. The shares were sold at an average price of $2.64 per share and generated approximately $2,895,000 in net proceeds.
In January, 2014, we closed a registered direct offering of 6,872,859 shares of common stock at a price of $2.91 per share. We received aggregate gross proceeds of $20 million and net proceeds of approximately $18,630,000 from the offering. In connection with the offering, we also issued 3,436,435 common stock purchase warrants; the warrants have an exercise price of $3.64, a term of five years and are classified within equity. This offering was made pursuant to our $50 million shelf registration statement declared effective by the SEC on September 13, 2013 (Registration No. 333-190936). Additionally, as a result of this transaction an advisor to the Company met certain capital raising milestones and consequently, the term of their common stock purchase warrant was extended to 5 years.
During the nine months ended September 30, 2014, we issued 249,163 shares of common stock as a result of sales under our At the Market Offering Agreement. The shares were sold at an average price of $3.55 per share and we received approximately $838,000 in net proceeds.
During the nine months ended September 30, 2014, we issued a total of 1,234,428 shares of our common stock upon the exercise of outstanding common stock purchase warrants and stock options. The warrants and options were exercised at an average exercise price of $1.44. We received approximately $1,758,000 of net proceeds from the exercises.
During the nine months ended September 30, 2014, we issued a total of 712,252 shares of our common stock upon the cashless and partial-cashless exercise of 1,193,891 outstanding common stock purchase warrants and stock options. The warrants and options were exercised at an average price of $1.03. We received approximately $20,000 of net proceeds from the exercises.
In September 2014, we issued 568 shares of common stock upon conversion of certain outstanding RSU’s. We received no proceeds from this transaction.
In September 2014, we issued 200,371 shares of common stock upon the conversion by the lender of approximately $249,000 of principal payments due under our March 2013 long-term debt in accordance with the terms of the loan and security agreement. We received no such proceeds from this conversion.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 6. Commitments and Contingencies
	We are parties to legal proceedings that we believe to be ordinary, routine litigation incidental to the business of present or former operations. It is management’s opinion, based on the advice of counsel, that the ultimate resolution of such litigation will not have a material adverse effect on our financial condition, results of operations or cash flows.
	On May 7, 2008, we filed suit against StemCells, Inc., StemCells California, Inc. (collectively "StemCells") and Neurospheres Holding Ltd. in U.S. District Court for the District of Maryland, alleging that U.S. Patent No. 7,361,505 (the "'505 patent") is invalid, not infringed, and unenforceable. See Civil Action No. 08-1173. On May 13, we filed an Amended Complaint seeking declaratory judgment that U.S. Patent No. 7,155,418 (the "'418 patent") is invalid and not infringed and that certain statements made by our CEO are not trade libel or do not constitute unfair competition. On September 11, 2008, StemCells filed its answer asserting counterclaims of infringement for the '505 patent, the '418 patent, and state law claims for trade libel and unfair competition. This case was consolidated with the 2006 litigation discussed below and it is not known when, nor on what basis, this matter will be concluded.
	On July 28, 2006, StemCells, Inc., filed suit against Neuralstem, Inc. in the U.S. District Court in Maryland, alleging that Neuralstem has been infringing, contributing to the infringement of, and or inducing the infringement of four patents allegedly owned by or exclusively licensed to StemCells. See Civil Action No. 06-1877. We answered the Complaint denying infringement, asserting that the patents are invalid, asserting that we have intervening rights based on amendments made to the patents during reexamination proceedings, and further asserting that some of the patents are unenforceable due to inequitable conduct. Neuralstem has also asserted counterclaims that StemCells has engaged in anticompetitive conduct in violation of antitrust laws. On February 28, 2011, Neuralstem filed a Motion to Dismiss for lack of standing and concurrently filed a Motion for Leave to Amend its Answer and Counterclaim to allege that StemCells is not the exclusive licensee of the patents-in-suit and also that Neuralstem has obtained a non-exclusive license to the patents-in-suit. In addition, before the Court decided Neuralstem's Motion to Dismiss for lack of standing, StemCells filed a motion for summary judgment on the issue standing. Neuralstem responded to that motion and cross-moved for summary judgment on the issue of standing. The Court further issued its Markman Order on August 12, 2011. On August 26, 2011, StemCells moved for reconsideration of two terms construed in the Markman Order and that motion remains pending. On April 6, 2012 the Court granted Neuralstem's Motion for Leave to Amend to assert lack of standing and denied Neuralstem's Motion to Dismiss and Motion for Summary Judgment without prejudice. The Court also denied StemCells' Motion for Summary Judgment with prejudice. The Court stayed all other matters pending resolution of the question of standing.
	On October 3, 2013, the Court ordered the parties to submit a joint status report regarding the status of the standing discovery. Following the submission the joint status report, the Court set a briefing schedule to resolve the standing issue. Before Neuralstem filed its opening brief on whether StemCells has standing, the case was reassigned to Judge Roger W. Titus from Judge Alexander Williams Jr.
	Neuralstem filed its opening brief in support of the standing issue on December 19, 2013. StemCells responded on January 21, 2014. Finally, Neuralstem filed its reply brief on February 4, 2014.   The issue will now be decided at a bench trial exclusively devoted to this issue beginning on December 9, 2014 which will either resolve the case in its entirety or will allow the case to move forward to expert discovery.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 7. Subsequent Events
	In October 2014, the Company and its existing lender entered into a modified loan and security agreement refinancing the Company’s March 2013 long term debt. The new agreement provides for $10 million in principal and resulted in approximately $4 million of net proceeds to the Company. In conjunction with the transaction the Company issued to the lender a common stock purchase warrant to purchase 75,188 shares of common stock at an exercise price of $2.66.

Significant_Accounting_Policie1

Significant Accounting Policies and Recent Accounting Pronouncements (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The condensed consolidated financial statements include significant estimates for the expected economic life and value of our licensed technology, our net operating loss carry forward and related valuation allowance for tax purposes and our stock-based compensation related to employees and directors, consultants and advisors, including investment banks, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.
Fair Value Measurement, Policy [Policy Text Block]	'
	Fair Value Measurements
	The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, other short-term investments, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The fair value of our long-term indebtedness is estimated based on the quoted prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. The fair values of our derivative instruments are estimated using Level 3 unobservable inputs. See Note 3 for further details.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	'
	Foreign Currency Translation
	The functional currency of our wholly owned foreign subsidiary is its local currency.  Assets and liabilities of our foreign subsidiary are translated into United States dollars based on exchange rates at the end of the reporting period; income and expense items are translated at the weighted average exchange rates prevailing during the reporting period.  Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of are accumulated in other comprehensive income or loss, a component of stockholders' equity.   Transaction gains or losses are included in the determination of net loss.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash, Cash Equivalents, Short-Term Investments and Credit Risk
	Cash equivalents consist of investments in low risk, highly liquid money market funds and certificates of deposit with original maturities of 90 days or less. Cash deposited with banks and other financial institutions may exceed the amount of insurance provided on such deposits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.
	Short-term investments consist entirely of fixed income certificates of deposit (“CDs”) with original maturities of greater than 90 days and not more than one year. The Company did not have any short-term investments at December 31, 2013.
	Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents and short-term investments. Our investment policy, approved by our Board of Directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. In addition, our CDs are invested through the Certificate of Deposit Account Registry Service (“CDARS”) program which reduces or eliminates our risk related to concentrations of investments above FDIC insurance levels. We limit our credit and liquidity risks through our investment policy and through regular reviews of our portfolio against our policy. To date, we have not experienced any loss or lack of access to cash in our operating accounts or to our cash equivalents and short-term investments.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	Historically, our revenue has been derived primarily from (i) selling treated samples for gene expression data from stem cell experiments, (ii) providing services under various contracts and grants and (iii) licensing the use of our intellectual property to third parties. Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery of goods and services has occurred, the price is fixed and determinable, and collection is reasonably assured.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development
	Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of costs associated exclusively with the pre-clinical development and clinical trials of our product candidates.
Earnings Per Share, Policy [Policy Text Block]	'
	Income (Loss) per Common Share
	Basic income (loss) per common share is computed by dividing total net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
	For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of stock options, restricted stock units and common stock purchase warrants. The dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. Our unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator.
	For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share for the three- and nine-month periods ended September 30, 2014 and 2013. A total of approximately 40.1 million and 36.1 million potential dilutive shares have been excluded in the calculation of diluted net income per share for the three- and nine-month periods ended September 30, 2014 and 2013, respectively, as their inclusion would be anti-dilutive.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Share-Based Compensation
	We account for share-based compensation at fair value. Share-based compensation cost for stock options and warrants is determined at the grant date using an option pricing model that uses Level 3 unobservable inputs; share-based compensation cost for restricted stock and restricted stock units is determined at the grant date based on the closing price of our common stock on that date. The value of the award that is ultimately expected to vest is recognized as an expense on a straight-line basis over the requisite service period.
Goodwill and Intangible Assets, Policy [Policy Text Block]	'
	Intangible and Long-Lived Assets
	We assess impairment of our long-lived assets using a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. During the three- and nine-month periods ended September 30, 2014 and 2013, no impairment losses were recognized.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. Our income tax returns for the past three years are subject to examination by tax authorities and may change upon examination.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Significant New Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (FASB) issued ASU 2014-09 – Revenue from Contracts with Customers. This guidance is effective for fiscal years beginning after December 15, 2016 and early adoption is not permitted. We have not yet determined the effects of this new guidance on our financial statements.
	In August 2014, the FASB issued ASU 2014 – Presentation of Financial Statements – Going Concern. This guidance requires management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. This guidance is effective for fiscal years beginning after December 15, 2016 and early adoption is permitted. We do not expect the adoption of this guidance to have a material impact on our financial statements.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	'
	The following table identifies the carrying amounts of such assets and liabilities at December 31, 2013:
		Level 1		Level 2		Level 3		Total
	Liabilities
	Derivative instruments - stock purchase warrants	$	-	$	-	$	1,417,527	$	1,417,527
		$	-	$	-	$	1,417,527	$	1,417,527
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 inputs for the nine months ended September 30, 2013 and 2014:
		Derivative		Contingent Stock
		Instruments - Stock		Options
		Purchase Warrants
	Balance at December 31, 2012	$	-	$	-
	Issuance		452,198		35,000
	Change in fair value		859,682		74,602
	Balance at September 30, 2013	$	1,311,880	$	109,602
		Derivative
		Instruments - Stock
		Purchase Warrants
	Balance at December 31, 2013	$	1,417,527
	Change in fair value		334,133
	Exercise of underlying warrants		-1,751,660
	Balance at September 30, 2014	$	-

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Activity [Table Text Block]	'
	Share-based compensation expense included in the statements of operations for the three and nine months ended September 30, 2014 and 2013 was as follows:
		Three Months Ended September 30,
		2014			2013
	Research and development expenses	$	245,000		$	241,934
	General and administrative expenses		411,947			765,519
	Total	$	656,947		$	1,007,453
		Nine Months Ended September 30,
		2014			2013
	Research and development expenses	$	723,558		$	690,199
	General and administrative expenses		2,915,414			1,390,541
	Total	$	3,638,972		$	2,080,740
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of stock option activity during the nine months ended September 30, 2014 is as follows:
		Number of Options			Weighted-		Weighted-		Aggregate
					Average		Average		Intrinsic Value
					Exercise		Remaining
					Price		Contractual
							Life (in years)
	Outstanding at January 1, 2014		18,577,207		$	1.79		5.8	$	24,000,710
	Granted		863,393		$	3.26
	Exercised		-322,231		$	0.89			$	1,310,344
	Forfeited		-282,789		$	1.2
	Outstanding at September 30, 2014		18,835,580		$	1.89		5.3	$	27,950,386
	Exercisable at September 30, 2014		14,014,963		$	2.07		4.4	$	18,523,332
	Vested and expected to vest		18,835,580		$	1.89		5.3	$	27,950,386
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
	Range of Exercise Prices	Number of Options			Weighted-		Weighted-		Aggregate
		Outstanding			Average		Average		Intrinsic Value
					Exercise		Remaining
					Price		Contractual
							Life (in years)
	$0.50 - $1.00		7,000,000		$	0.8		5.8	$	17,360,000
	$1.01 - $2.00		4,171,817		$	1.19		6.9		8,714,368
	$2.01 - $3.00		2,067,037		$	2.48		4.7		1,646,933
	$3.01 - $5.00		5,596,726		$	3.54		3.8		229,085
			18,835,580		$	1.89		5.3	$	27,950,386
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Black Sholes Model [Table Text Block]	'
	The Company uses the Black-Scholes option pricing model for “plain vanilla” options and other pricing models as appropriate to calculate the fair value of options. Significant assumptions used in these models include:
		Nine Months Ended September 30,
		2014		2013
	Annual dividend	-		-
	Expected life (in years)	4.0 - 8.5		3.0 - 6.0
	Risk free interest rate	1.12% - 2.50%		0.51% - 1.01%
	Expected volatility	68.8% - 100.0%		65.1% - 75.2%
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	'
	A summary of our restricted stock unit activity for the nine months ended September 30, 2014 is as follows:
		Number of			Weighted-
		RSU's			Average
					Grant Date
					Fair Value
	Outstanding at January 1, 2014		401,625		$	2.03
	Granted		50,000		$	3.31
	Vested and converted to common shares		-568		$	1.19
	Forfeited		-3,782		$	1.19
	Outstanding at September 30, 2014		447,275		$	2.18
	Exercisable at September 30, 2014		427,416		$	2.15
Schedule Of Share Based Compensation Warrant Activity [Table Text Block]	'
	A summary of warrant activity for the nine months ended September 30, 2014 is as follows:
		Number of			Weighted-		Weighted-		Aggregate
		Warrants			Average		Average		Intrinsic
					Exercised		Remaining		Value
					Price		Contractual Life
							(in years)
	Outstanding at January 1, 2014		19,586,819		$	1.96		3.4	$	21,146,495
	Granted		3,586,435		$	3.66		4.3
	Exercised		-1,624,449		$	1.36
	Forfeited		-259,788		$	1.23
	Outstanding at September 30, 2014		21,289,017		$	2.3		4	$	23,900,186
	Exercisable at September 30, 2014		21,176,517		$	2.28		4	$	23,900,186

Significant_Accounting_Policie2

Significant Accounting Policies and Recent Accounting Pronouncements (Details Textual)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Significant Accounting Policies [Line Items]	'	'
Policy For Maximum Maturity Days Of Investments Considered As Cash Equivalents	'90 days	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	40.1	36.1

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Derivatives, Fair Value [Line Items]	'	'
Derivative instruments - stock purchase warrants	$0	$1,417,527
Warrant [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative instruments - stock purchase warrants	'	1,417,527
Fair Value, Inputs, Level 1 [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative instruments - stock purchase warrants	'	0
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative instruments - stock purchase warrants	'	0
Fair Value, Inputs, Level 2 [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative instruments - stock purchase warrants	'	0
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative instruments - stock purchase warrants	'	0
Fair Value, Inputs, Level 3 [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative instruments - stock purchase warrants	'	1,417,527
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative instruments - stock purchase warrants	'	$1,417,527

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 1) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Employee Stock Option [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Balance at beginning	'	$0
Issuance	'	35,000
Change in fair value	'	74,602
Balance at ending	'	109,602
Warrant [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Balance at beginning	1,417,527	0
Issuance	'	452,198
Change in fair value	334,133	859,682
Exercise of underlying warrants	-1,751,660	'
Balance at ending	$0	$1,311,880

Debt_Details_Textual

Debt (Details Textual) (USD $)	1 Months Ended		9 Months Ended
	Sep. 30, 2014	Mar. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013
Debt Instrument [Line Items]	'	'	'	'	'
Debt Instrument, Face Amount	'	$8,000,000	'	'	'
Debt Instrument, Unused Borrowing Capacity, Amount	'	2,000,000	'	'	'
Debt Instrument, Interest Rate at Period End	11.00%	'	11.00%	'	11.00%
Debt Instrument, Maturity Date	'	'	30-Jun-16	'	'
Debt Instrument, Weighted Average Interest Rate	'	'	11.00%	'	'
Proceeds from Debt, Net of Issuance Costs	'	'	7,551,000	'	'
Stock Issued During Period, Shares, New Issues	'	350,650	'	'	'
Debt Instrument, Debt Default, Amount	'	'	'	300,000	'
Debt Conversion, Original Debt, Amount	249,000	'	'	'	'
Debt Conversion, Converted Instrument, Shares Issued	200,371	'	'	'	'
Maturity 2014 [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Debt Instrument, Face Amount	763,000	'	763,000	'	'
Maturity 2015 [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Debt Instrument, Face Amount	3,273,000	'	3,273,000	'	'
Maturity 2016 [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Debt Instrument, Face Amount	1,797,000	'	1,797,000	'	'
Warrant One [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Number Of Common Stock Shares Granted By Issue Of Warrants	'	'	648,809	'	'
Exercise Price Per share Of Common Stock To Be Issued Upon Conversion Of Warrants	'	'	$1.08	'	'
Warrants Expiration Period	'	'	'5 years	'	'
Warrant Two [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Debt Issuance Cost	'	'	449,000	'	'
Stock Issued During Period, Shares, New Issues	'	'	350,650	'	'
Number Of Common Stock Shares Granted By Issue Of Warrants	'	'	648,798	'	'
Exercise Price Per share Of Common Stock To Be Issued Upon Conversion Of Warrants	'	'	$1.08	'	'
Stock Issued During Period, Value, New Issues	'	'	$396,000	'	'
Warrants Expiration Period	'	'	'5 years	'	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Stockholders Equity [Line Items]	'	'	'	'
Total	$656,947	$1,007,453	$3,638,972	$2,080,740
Research and Development Expense [Member]	'	'	'	'
Stockholders Equity [Line Items]	'	'	'	'
Total	245,000	241,934	723,558	690,199
General and Administrative Expense [Member]	'	'	'	'
Stockholders Equity [Line Items]	'	'	'	'
Total	$411,947	$765,519	$2,915,414	$1,390,541

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Stockholders Equity [Line Items]	'	'
Outstanding, Number of Options, at January 1, 2014	18,577,207	'
Granted, Number of Options	863,393	'
Exercised, Number of Options	-322,231	'
Forfeited, Number of Options	-282,789	'
Outstanding, Number of Options, at September 30, 2014	18,835,580	18,577,207
Exercisable, Number of Options, at September 30, 2014	14,014,963	'
Vested and expected to vest, Number of Options	18,835,580	'
Outstanding, Weighted-Average Exercise Price, at January 1, 2014	$1.79	'
Granted, Weighted-Average Exercise Price	$3.26	'
Exercised, Weighted-Average Exercise Price	$0.89	'
Forfeited, Weighted-Average Exercise Price	$1.20	'
Outstanding, Weighted-Average Exercise Price, at September 30, 2014	$1.89	$1.79
Exercisable, Weighted-Average Exercise Price, at September 30, 2014	$2.07	'
Vested and expected to vest, Weighted-Average Exercise Price	$1.89	'
Outstanding, Weighted-Average Remaining Contractual Life (in Years)	'5 years 3 months 18 days	'5 years 9 months 18 days
Exercisable, Weighted-Average Remaining Contractual Life (in Years)	'4 years 4 months 24 days	'
Vested and expected to vest, Weighted-Average Remaining Contractual Life (in Years)	'5 years 3 months 18 days	'
Outstanding, Aggregate Intrinsic Value, at January 1, 2014	$24,000,710	'
Exercised, Aggregate Intrinsic Value	1,310,344	'
Outstanding, Aggregate Intrinsic Value, at September 30, 2014	27,950,386	24,000,710
Exercisable, Aggregate Intrinsic Value, at September 30, 2014	18,523,332	'
Vested and expected to vest, Aggregate Intrinsic Value	$27,950,386	'

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (USD $)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Stockholders Equity [Line Items]	'	'
Number of Options Outstanding	18,835,580	'
Weighted-Average Exercise Price	$1.89	$1.79
Weighted-Average Remaining Contractual Life (in Years)	'5 years 3 months 18 days	'
Aggregate Intrinsic Value	$27,950,386	$24,000,710
Range One [Member]	'	'
Stockholders Equity [Line Items]	'	'
Range of Exercise Price (Lower)	$0.50	'
Range of Exercise Price (Upper)	$1	'
Number of Options Outstanding	7,000,000	'
Weighted-Average Exercise Price	$0.80	'
Weighted-Average Remaining Contractual Life (in Years)	'5 years 9 months 18 days	'
Aggregate Intrinsic Value	17,360,000	'
Range Two [Member]	'	'
Stockholders Equity [Line Items]	'	'
Range of Exercise Price (Lower)	$1.01	'
Range of Exercise Price (Upper)	$2	'
Number of Options Outstanding	4,171,817	'
Weighted-Average Exercise Price	$1.19	'
Weighted-Average Remaining Contractual Life (in Years)	'6 years 10 months 24 days	'
Aggregate Intrinsic Value	8,714,368	'
Range Three [Member]	'	'
Stockholders Equity [Line Items]	'	'
Range of Exercise Price (Lower)	$2.01	'
Range of Exercise Price (Upper)	$3	'
Number of Options Outstanding	2,067,037	'
Weighted-Average Exercise Price	$2.48	'
Weighted-Average Remaining Contractual Life (in Years)	'4 years 8 months 12 days	'
Aggregate Intrinsic Value	1,646,933	'
Range Four [Member]	'	'
Stockholders Equity [Line Items]	'	'
Range of Exercise Price (Lower)	$3.01	'
Range of Exercise Price (Upper)	$5	'
Number of Options Outstanding	5,596,726	'
Weighted-Average Exercise Price	$3.54	'
Weighted-Average Remaining Contractual Life (in Years)	'3 years 9 months 18 days	'
Aggregate Intrinsic Value	$229,085	'

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Stockholders Equity [Line Items]	'	'
Annual dividend	0.00%	0.00%
Minimum [Member]	'	'
Stockholders Equity [Line Items]	'	'
Expected life (in years)	'4 years	'3 years
Risk free interest rate	1.12%	0.51%
Expected volatility	68.80%	65.10%
Maximum [Member]	'	'
Stockholders Equity [Line Items]	'	'
Expected life (in years)	'8 years 6 months	'6 years
Risk free interest rate	2.50%	1.01%
Expected volatility	100.00%	75.20%

Stockholders_Equity_Details_4

Stockholders' Equity (Details 4) (Restricted Stock Units (RSUs) [Member], USD $)	9 Months Ended
	Sep. 30, 2014
Restricted Stock Units (RSUs) [Member]	'
Stockholders Equity [Line Items]	'
Outstanding Number of RSU's at January 1, 2014	401,625
Granted Number of RSU's	50,000
Vested and converted to common shares Number of RSUs	-568
Forfeited Number of RSU's	-3,782
Outstanding Number of RSU's at September 30, 2014	447,275
Exercisable Number of RSU's at September 30, 2014	427,416
Outstanding Weighted-Average Grant Date Fair Value at January 1, 2014	$2.03
Granted Weighted-Average Grant Date Fair Value	$3.31
Vested and converted to common shares Weighted-Average Grant Date Fair Value	$1.19
Forfeited Weighted-Average Grant Date Fair Value	$1.19
Outstanding Weighted-Average Grant Date Fair Value at September 30, 2014	$2.18
Exercisable Weighted-Average Grant Date Fair Value at September 30, 2014	$2.15

Stockholders_Equity_Details_5

Stockholders' Equity (Details 5) (Warrant [Member], USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Warrant [Member]	'	'
Stockholders Equity [Line Items]	'	'
Outstanding Number of Warrants at January 1, 2014	19,586,819	'
Granted Number of Warrants	3,586,435	'
Exercised Number of Warrants	-1,624,449	'
Forfeited Number of Warrants	-259,788	'
Outstanding Number of Warrants at September 30, 2014	21,289,017	19,586,819
Exercisable Number of Warrants	21,176,517	'
Outstanding Weighted-Average Exercise Price, at January 1, 2014	$1.96	'
Granted Weighted-Average Exercise Price	$3.66	'
Exercised Weighted-Average Exercise Price	$1.36	'
Forfeited Weighted Average Exercise Price	$1.23	'
Outstanding Weighted-Average Exercise Price, at September 30, 2014	$2.30	$1.96
Exercisable Weighted-Average Exercise Price, at September 30, 2014	$2.28	'
Outstanding Weighted-Average Remaining Contractual Life (in years)	'4 years	'3 years 4 months 24 days
Granted Weighted-Average Remaining Contractual Life (in years)	'4 years 3 months 18 days	'
Exercisable Weighted-Average Remaining Contractual Life (in years), at September 30, 2014	'4 years	'
Outstanding Aggregate Intrinsic Value, at January 1, 2014	$21,146,495	'
Outstanding Aggregate Intrinsic Value, at September 30, 2014	23,900,186	21,146,495
Exercisable Aggregate Intrinsic Value, at September 30, 2014	$23,900,186	'

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)

1 Months Ended

2 Months Ended

9 Months Ended

2 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

4 Months Ended

9 Months Ended

1 Months Ended

2 Months Ended

1 Months Ended

2 Months Ended

1 Months Ended

4 Months Ended

1 Months Ended

4 Months Ended

9 Months Ended

1 Months Ended

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2013

Feb. 28, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2014

Sep. 13, 2013

Jan. 31, 2014

Sep. 30, 2013

Jul. 31, 2013

31-May-13

Sep. 30, 2014

Jul. 31, 2013

31-May-13

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Market Offering Agreement [Member]

Market Offering Agreement [Member]

Direct Offering [Member]

Direct Offering [Member]

Phase One [Member]

Phase One [Member]

Phase One [Member]

Phase One [Member]

Phase Two [Member]

Phase Two [Member]

Phase Two [Member]

Phase Two [Member]

Phase three [Member]

Phase three [Member]

Phase Four [Member]

Phase Four [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Warrant [Member]

Warrant [Member]

Restricted Stock Units (RSUs) [Member]

Private Placement [Member]

Phase One [Member]

Phase Two [Member]

Phase One [Member]

Phase Two [Member]

Phase Four [Member]

Stockholders Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

'

'

'

'

$1.93

$0.69

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.09

$0.82

'

'

Warrants Issued During Period

'

'

'

258,000

'

'

'

'

'

'

3,436,435

'

942,520

440,000

'

100,000

689,675

'

'

'

378,809

'

300,000

648,798

4,000

800,000

340,000

'

'

'

170,850

Class Of Warrant Or Right Exercise Price Of Warrants Issued

'

'

'

$1.25

'

'

'

'

'

'

'

'

$1.25

$1.07

$1.44

'

$1.25

'

$1.03

$0.90

'

$2

'

'

'

'

'

'

'

'

$2

Share Price

'

'

'

$1.25

'

'

'

'

$3.55

'

$2.91

'

$1.25

$1.07

'

$1.02

$1.25

'

'

'

$1.25

$1.60

$1.02

$1.08

$1.56

$1.25

$2.13

'

'

'

'

Stock Issued During Period Share From Warrants In Conjunction With Debt Transaction

'

'

1,297,607

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4,556,000

'

'

'

'

'

'

'

'

'

Net proceeds received from issuance

'

'

'

323,000

'

'

'

2,895,000

838,000

'

18,630,000

1,700,000

1,178,000

433,000

1,758,000

102,000

844,000

730,000

20,000

'

474,000

4,242,000

306,000

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

350,650

'

'

'

'

1,140,994

249,163

'

'

72,440

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock from warrants exercised (in shares)

'

'

'

258,000

'

'

'

'

'

'

'

1,448,798

942,520

440,000

1,234,428

'

689,675

344,000

712,252

401,133

378,809

1,423,750

'

'

'

'

'

'

'

'

'

Warrants Expiration Date

'

'

'

'2020-03-31

'

'

'

'

'

'

'

'

'2020-03-31

'2016-05-31

'

'

'2020-03-31

'

'

'

'2020-03-31

'

'

'

'

'

'

'

'

'

'

Warrants Modified During Period

'

'

'

'

'

'

'

'

'

'

'

'

782,005

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Forfeited During Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

248,867

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Shares Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,847,500

'

'

'

'

'

'

'

'

'

Stock or Unit Option Plan Expense

'

'

'

'

4,708,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation Expenses Unvested stock option term period

'

'

'

'

'2 years 2 months 12 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation Expenses Unvested Restricted Stock term period

'

'

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Price Per Share

'

'

'

'

'

'

'

$2.64

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercisable Years

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'19 months

Shelf Registration Amount During Public Offering

'

'

'

'

'

'

'

'

'

'

6,872,859

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance Initial Public Offering

'

'

'

'

'

'

'

'

'

50,000,000

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Capital Shares Reserved for Future Issuance

44,400,000

'

'

'

44,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation Expenses Unvested Restricted Stock,Outstanding Value

'

'

'

'

45,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

$1.25

'

'

'

'

'

'

$3.64

'

$1.25

$1.25

'

'

$1.25

'

'

'

$1.25

'

'

'

'

'

'

'

'

'

'

Class Of Warrant Or Right Expense Recognized

'

'

'

'

3,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase Decrease in Common Stock, Shares Authorized

'

150,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance Of Common Stock From Cashless Exercise

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,193,891

650,000

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,624,449

'

568

'

Debt Conversion, Converted Instrument, Shares Issued

200,371

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Original Debt, Amount

$249,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized

300,000,000

300,000,000

'

'

300,000,000

'

300,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Subsequent_Events_Details_text

Subsequent Events (Details textual) (USD $)	9 Months Ended
	Sep. 30, 2014
Subsequent Event [Line Items]	'
Proceeds from Debt, Net of Issuance Costs	$7,551,000
Subsequent Event [Member]	'
Subsequent Event [Line Items]	'
Debt Instrument, Face Amount	10,000,000
Proceeds from Debt, Net of Issuance Costs	$4,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award	75,188
Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased	$2.66